Company news
Amgen Inc. news in 2022
Amgen Inc.'s news releases, calls and decks from 2022, newest first.
BLINCYTO® (blinatumomab) added to consolidation chemotherapy significantly improves survival in adult patients with measurable residual disease-negative b-lineage acute lymphoblastic leukemia (B-ALL)
December 12, 2022
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
December 11, 2022
Amgen to host webcast investor call following announced acquisition of horizon therapeutics
December 11, 2022
Amgen announces 10% increase in 2023 first quarter dividend
December 11, 2022
Amgen presents new AMG 133 Phase 1 clinical data at WCIRDC 2022
November 30, 2022
Amgen to webcast investor call at wcirdc 2022
November 27, 2022
Amgen announces webcast of 2022 evercore isi healthcare conference
November 22, 2022
Amgen to present new research across serious inflammatory and Bone diseases at ACR 2022
November 6, 2022
Amgen presents new repatha® (evolocumab) data at aha 2022
November 6, 2022
Amgen presents new Phase 2 data that show olpasiran delivers significant reduction in lipoprotein(a) levels
November 5, 2022
Amgen announces webcast of 2022 credit suisse global healthcare conference
November 3, 2022
Amgen reports third quarter 2022 financial results
November 2, 2022
Amgen to webcast investor call at AHA 2022
November 1, 2022
Amgen announces webcast of 2022 third quarter financial results
October 30, 2022
Amgen announces 2022 fourth quarter dividend
October 27, 2022
Amgen successfully completes acquisition of ChemoCentryx
October 19, 2022
Amgen's annual trends report finds competition created by biosimilars contributed $21 billion in U.S. healthcare system savings
October 11, 2022
Amgen opens new state-of-the-art research and development laboratory site in San Francisco bay area
October 5, 2022
LUMAKRAS® (sotorasib) combined with Vectibix® (panitumumab) shows confirmed 30% objective response rate in patients with KRAS G12C-mutated metastatic colorectal cancer
September 11, 2022
Amgen announces webcast of 2022 bank of america merrill lynch global healthcare conference
September 11, 2022
LUMAKRAS®/LUMYKRAS® (sotorasib) demonstrates superior progression-free survival over docetaxel in first positive Phase 3 trial of a KRAS G12C inhibitor in non-small cell lung cancer
September 10, 2022
Amgen announces webcast of 2022 morgan stanley global healthcare conference
September 7, 2022
Amgen announces positive new data at eadv 2022 for Otezla® (apremilast)
September 7, 2022
Amgen to webcast investor call at esmo 2022
September 6, 2022
Amgen announces webcast of 2022 wells fargo healthcare conference
September 1, 2022
Amgen announces webcast of 2022 citi global healthcare conference
September 1, 2022
Amgen to present new, positive clinical and real-world data across inflammation portfolio at EADV 2022
August 29, 2022
Amgen announces topline data from LUMAKRAS® (sotorasib) Phase 3 trial in non-small cell lung cancer
August 29, 2022
Amgen announces positive top-line results from Phase 3 study of ABP 959, biosimilar candidate to SOLIRIS® (eculizumab)
August 22, 2022
Amgen reports second quarter 2022 financial results
August 3, 2022
Amgen appoints Michael V. Drake to board of directors
August 2, 2022
Amgen announces webcast of 2022 second quarter financial results
July 31, 2022
Amgen announces webcast of 2022 jefferies healthcare conference
June 2, 2022
Amgen announces positive topline Phase 2 data for investigational olpasiran in adults with elevated Lipoprotein(a)
May 30, 2022
Amgen and Lance Bass partner to encourage people to do a 'Double Take' to recognize the early signs of psoriatic arthritis
May 11, 2022
Amgen releases annual environmental, social & governance report
May 1, 2022
Amgen announces results from two open label extension studies of Repatha® (evolocumab)
April 26, 2022
Amgen announces positive top-line results from Phase 3 study of ABP 654, biosimilar candidate to STELARA® (ustekinumab)
April 17, 2022
Amgen announces new Otezla (apremilast) data at AAD congress 2022
March 24, 2022
Amgen to present long-term outcomes for LUMAKRAS® (sotorasib) in KRAS G12C-mutated NSCLC at AACR 2022
March 7, 2022
Global biotechnology leader Amgen breaks ground on new manufacturing facility in North Carolina
March 6, 2022
Amgen announces 2022 second quarter dividend
March 1, 2022
Amgen issues inaugural green bond to advance ESG goals
February 21, 2022
Amgen outlines growth strategy through 2030 at virtual business review
February 7, 2022
Amgen reports fourth quarter and full year 2021 financial results
February 6, 2022
Amgen and Plexium announce multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies
February 2, 2022
Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule Therapeutics
January 10, 2022
Amgen and BioLabs LA at The Lundquist Institute announce that Karma Biotechnologies will receive the second Amgen Golden Ticket
January 9, 2022
Amgen and Generate Biomedicines announce multi-target, multi-modality research collaboration agreement
January 5, 2022
Calls in 2022
Decks in 2022
- Q2 2022 Earnings Presentation
Earnings · 49 slides · Aug 4, 2022